Become an Investigator
Help find solutions for Targeted Therapy-Induced Diarrhea by becoming an OnTarget Investigator
Learn if you’re qualified to be an OnTarget investigator and enroll patients in this study
The OnTarget supportive care study is a phase 3, multicenter, randomized clinical trial (Protocol NP303-102) evaluating the effectiveness of the novel drug, crofelemer, in the prophylaxis of diarrhea in adult patients with solid tumors receiving targeted therapies with or without chemotherapy. Crofelemer is an FDA-approved drug with an established safety profile and demonstrated efficacy for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.
Only patients who have not begun targeted therapy and are not scheduled for immunotherapy are eligible for this trial.
Cancer treatment-related diarrhea (CTD) is a common and sometimes severe side effect for which supportive care solutions are critically needed. CTD often necessitates dose reductions and treatment breaks, which may compromise clinical outcomes. CTD also can affect patients’ ability to receive proper nutrition, which is key to their treatment success and overall health.
Because targeted therapies show much promise and are increasingly used for treating solid tumors, preventing and mitigating diarrhea is critical for both treatment adherence and patient quality of life.
Learn if you’re eligible to become an investigator by completing and submitting our short interest survey.
Crofelemer reduces intestinal chloride ion and fluid secretion. In various clinical trials, it demonstrated efficacy when compared to placebo in reducing loose or watery bowl movement frequency and improving stool consistency.
The pivotal phase 3 Advent clinical trial in HIV/AIDS patients receiving antiretroviral therapy led to approval of crofelemer at a twice-daily, 125-mg. dose for the symptomatic relief of noninfectious diarrhea in these patients.
Crofelemer was well-tolerated in HIV+ individuals with diarrhea in multiple clinical studies. It is not systemically absorbed and has no known drug-drug interactions.